Trials / Unknown
UnknownNCT04128085
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
A Phase I, Open-label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3804 in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3804 | A kind of tyrosine kinase inhibitor. |
Timeline
- Start date
- 2019-11-15
- Primary completion
- 2020-10-01
- Completion
- 2021-10-01
- First posted
- 2019-10-16
- Last updated
- 2019-12-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04128085. Inclusion in this directory is not an endorsement.